Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01959230 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Brimonidine Tartrate Ophthalmic Solution in Adult and Geriatric Participants With Ocular Redness
A Phase 3 study, sponsored by Bausch & Lomb Incorporated.
- Completed
- Registry status
- Phase 3
- Development phase
- 60
- Enrollment target
NCT01959230 is a Phase 3 study that has completed, run by Bausch & Lomb Incorporated. The registered enrollment target is 60 participants.
The verdict
NCT01959230, a Phase 3 study, has completed, sponsored by Bausch & Lomb Incorporated.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 60 participants
- Enrollment target
Study Summary
To compare the efficacy and safety of brimonidine tartrate ophthalmic solution 0.025% with its vehicle for the treatment of ocular redness in a population of adult and geriatric participants with ocular redness.
Interventions
- DRUG Vehicle
- DRUG Brimonidine Tartrate
- DRUG Sodium Fluorescein
- DRUG Fluorescein Sodium and Benoximate Hydrocholoride Ophthalmic Solution USP
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2013-11-07 |
| Est. Completion | 2013-12-20 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01959230
The ClinicalTrials.gov registry entry for NCT01959230 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bausch & Lomb Incorporated, which has 174 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Vehicle is the first listed.
NCT01959230 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01959230 about?
NCT01959230 is a clinical study titled "Efficacy and Safety of Brimonidine Tartrate Ophthalmic Solution in Adult and Geriatric Participants With Ocular Redness". To compare the efficacy and safety of brimonidine tartrate ophthalmic solution 0.025% with its vehicle for the treatment of ocular redness in a population of adult and geriatric participants with ocular redness.
What is the current status of trial NCT01959230?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 60 participants. The study started on 2013-11-07. Estimated completion is 2013-12-20.
What interventions are being tested in trial NCT01959230?
The interventions under investigation include: Vehicle (DRUG), Brimonidine Tartrate (DRUG), Sodium Fluorescein (DRUG), Fluorescein Sodium and Benoximate Hydrocholoride Ophthalmic Solution USP (DRUG).
Who is sponsoring clinical trial NCT01959230?
This trial is sponsored by Bausch & Lomb Incorporated, which has 174 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.